A detailed history of Royal Bank Of Canada transactions in Galapagos Nv stock. As of the latest transaction made, Royal Bank Of Canada holds 1,073 shares of GLPG stock, worth $29,303. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,073
Previous 967 10.96%
Holding current value
$29,303
Previous $23,000 30.43%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$24.2 - $30.67 $2,565 - $3,251
106 Added 10.96%
1,073 $30,000
Q2 2024

Aug 14, 2024

BUY
$24.78 - $32.48 $1,338 - $1,753
54 Added 5.91%
967 $23,000
Q1 2024

Nov 05, 2024

SELL
$32.2 - $42.44 $1,738 - $2,291
-54 Reduced 5.58%
913 $29,000
Q1 2024

May 15, 2024

SELL
$32.2 - $42.44 $322 - $424
-10 Reduced 1.08%
913 $29,000
Q4 2023

Feb 14, 2024

SELL
$31.87 - $40.71 $50,004 - $63,873
-1,569 Reduced 62.96%
923 $37,000
Q3 2023

Nov 14, 2023

SELL
$34.17 - $42.98 $785 - $988
-23 Reduced 0.91%
2,492 $86,000
Q2 2023

Aug 14, 2023

BUY
$37.4 - $44.52 $897 - $1,068
24 Added 0.96%
2,515 $102,000
Q4 2022

Feb 14, 2023

SELL
$37.44 - $46.51 $14,976 - $18,604
-400 Reduced 13.84%
2,491 $110,000
Q3 2022

Nov 14, 2022

BUY
$42.27 - $57.6 $253 - $345
6 Added 0.21%
2,891 $123,000
Q2 2022

Aug 15, 2022

SELL
$52.3 - $71.59 $11,087 - $15,177
-212 Reduced 6.85%
2,885 $162,000
Q1 2022

May 16, 2022

SELL
$51.32 - $68.5 $16,319 - $21,783
-318 Reduced 9.31%
3,097 $192,000
Q4 2021

Feb 14, 2022

BUY
$47.03 - $57.12 $10,957 - $13,308
233 Added 7.32%
3,415 $189,000
Q3 2021

Nov 15, 2021

BUY
$52.17 - $70.2 $34,275 - $46,121
657 Added 26.02%
3,182 $168,000
Q2 2021

Aug 16, 2021

BUY
$68.86 - $83.34 $173,871 - $210,433
2,525 New
2,525 $174,000

Others Institutions Holding GLPG

About GALAPAGOS NV


  • Ticker GLPG
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,835,500
  • Market Cap $1.8B
  • Description
  • Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...
More about GLPG
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.